Last reviewed · How we verify
NCT03886103
Pharmacokinetics and Metabolism of (14C)-Labelled PXL770
Phase 1 trial testing 14C labeled PXL770 in Healthy in 8 participants. Completed in 15 March 2019.
15 March 2019
Quick facts
| Lead sponsor | Poxel SA |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 6 February 2019 |
| Primary completion | 15 March 2019 |
| Estimated completion | 15 March 2019 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- 14C labeled PXL770 — full drug profile →
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Poxel SA — full company profile →
Who can join
Adults 30 to 65, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a single-dose, single center, single-period, open-label, non-randomized, mass balance recovery study in healthy male subjects.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Pharmacological advances in mitochondrial therapy.
Singh A, Faccenda D, Campanella M. · · 2021 · cited 88× · PMID 33647769 · DOI 10.1016/j.ebiom.2021.103244
Verify or expand the search:
- PubMed search for NCT03886103
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Poxel SA trials
Trials by the same sponsor.
- NCT05441904 — Study to Assess the Safety, Tolerability, and Pharmacokinetics of PXL770 in Healthy Subjects. · Phase 1 · completed
- NCT04321343 — Study of PXL065 in Patients With Nonalcoholic Steatohepatitis (NASH) · Phase 2 · completed
- NCT03950882 — A Study to Assess the Pharmacokinetics of PXL770 After 4 Weeks of Treatment in Subjects With NAFLD · Phase 1 · completed
- NCT03763877 — A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD · Phase 2 · completed
- NCT03802786 — Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03886103 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Poxel SA
- Last refreshed: 22 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03886103.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing